comparemela.com

Latest Breaking News On - Jamesm mackay - Page 1 : comparemela.com

Aristea Therapeutics Announces Discontinuation of RIST4721 Development Program and Decision to Dissolve the Company

/PRNewswire/ Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious.

Aristea Therapeutics Announces Dosing of First Patient in Phase 2a Trial of RIST4721 in Hidradenitis Suppurativa

/PRNewswire/ Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious.

Aristea Therapeutics Strengthens its Board of Directors with the Appointment of Three Accomplished Biopharma Leaders From Poseida Therapeutics, Novo Holdings and Pfizer

Aristea Therapeutics Strengthens its Board of Directors with the Appointment of Three Accomplished Biopharma Leaders From Poseida Therapeutics, Novo Holdings and Pfizer - read this article along with other careers information, tips and advice on BioSpace

Aristea Therapeutics Announces Dosing of First Patient in Open-Label Extension for Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis

/PRNewswire/ Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious.

Aristea initiates 2b trial of palmoplantar pustulosis candidate

Aristea Therapeutics has dosed the first patient in a phase 2b trial of its palmoplantar pustulosis candidate RIST4721, the company announced in a press release.A CXCR2 antagonist, RIST4721 is in development for the treatment of multiple inflammatory diseases, including the rare chronic skin condition palmoplantar pustulosis (PPP), which is characterized by recurrent sterile pustules on the palms

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.